May 23, 2026 03:36 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Big twist in RG Kar case! Calcutta HC orders fresh probe into evidence destruction allegations | Pulwama mastermind Hamza Burhan shot dead in PoK by unknown gunmen: Reports | NIA arrests Kolkata man for spying for Pakistan intelligence network | Cockroach Janta Party X handle withheld! Founder Abhijeet Dipke launches comeback account | Bengal govt makes Vande Mataram compulsory in all madrasas, extends school directive | RBI on alert! Interest rate hike may be coming as rupee crashes to fresh low | Big relief for Maharashtra employees! Fadnavis govt hikes DA to 60% | Twisha Sharma death mystery deepens as crucial evidence ‘not shared’ during autopsy: Report | Balcony Smiles, Colosseum Walks and ‘Melodi’ Magic: Modi-Meloni Chemistry Has The Internet Swooning Again | Big relief signal for Umar Khalid, Sharjeel Imam? Supreme Court questions earlier bail denial

Singapore to begin human clinical trials on potential coronavirus treatment - Reports

| @indiablooms | Jun 10, 2020, at 04:26 pm

Moscow/Sputnik/UNI: Singapore will begin human clinical trials on a domestically developed treatment candidate for the coronavirus next week, media reported Wednesday.

According to the Singapore news outlet, The Strait Times, biotechnology company Tychan will administer the experimental treatment to 23 healthy individuals and monitor the results over six weeks.

The medication in question is the TY027, which was developed to specifically target Sars-Cov-2, the virus that causes COVID-19, the newspaper reported.

The medication is being studied for qualities of slowing the spread of the virus, speeding up recovery and even protecting against the infection, according to The Strait Times.

Tychan is one of the dozens of companies around the world racing to develop treatments and vaccines against the coronavirus, which has so far infected more than 7.3 million people and killed over 410,000. 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.